PSNL
BEARISH
$6.73
Live
Personalis, Inc. · NASDAQ
Target $11.29
(+67.7%)
$3.09
52W Range
$11.5
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 18, 2026
Market cap
$704.48M
P/E
N/A
ROE
-35.0%
Profit margin
-116.7%
Debt/Equity
0.17
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
PSNL exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health and operational deterioration. Despite a 'Strong Buy' analyst consensus and a high current ratio, the company suffers from massive negative profit margins (-116.69%) and stagnant revenue growth (3.20%). The disconnect between analyst price targets and the deterministic data suggests a speculative valuation not supported by current earnings or growth trajectories. Insider selling by the CEO and COO further reinforces a bearish outlook.
Key Strengths
Strong liquidity position with a Current Ratio of 6.76
Low leverage with a Debt/Equity ratio of 0.17
Positive analyst sentiment with a target price of $11.29
Recent history of beating EPS estimates in 3 of the last 4 quarters
Low total debt relative to equity
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Severe lack of profitability with operating margins at -145.67%
Stagnant revenue growth (3.20% YoY) for a diagnostics growth company
Bearish insider activity with significant sales from the CEO and COO
High valuation relative to sales (P/S of 10.11) despite poor growth
AI Fair Value Estimate
Based on comprehensive analysis
$4.5
-33.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
30
25
35
15
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Profit Margins, Stagnant Revenue Growth, Insider Selling
Confidence
90%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book is moderate at 2.64
Watchpoints
- Price/Sales of 10.11 is excessive for 3% growth
- No Graham Number due to lack of earnings
Future
25/100
Ref Growth rates
Positives
- Analyst target price suggests 68% upside
Watchpoints
- YoY Revenue growth of 3.20% is anemic for the sector
- Negative EPS growth trends
Past
35/100
Ref Historical trends
Positives
- 1Y return of +111% shows recent momentum
Watchpoints
- 5Y change is -68.6%
- Consistent history of negative EPS
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High Current Ratio (6.76)
- Low Debt/Equity (0.17)
Watchpoints
- Piotroski F-Score of 1/9 indicates extreme weakness
- Negative ROE and ROA
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$6.73
Analyst Target
$11.29
Upside/Downside
+67.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PSNL and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PSNL
Personalis, Inc.
Primary
|
-68.6% | +152.1% | +111.0% | -26.3% | -3.3% | +11.8% |
|
BBNX
Beta Bionics, Inc.
Peer
|
-32.5% | -32.5% | -32.5% | +7.5% | -48.7% | -13.7% |
|
GYRE
Gyre Therapeutics, Inc.
Peer
|
-40.0% | +134.6% | +1.4% | -7.2% | -11.3% | +3.8% |
|
ETON
Eton Pharmaceuticals, Inc.
Peer
|
+251.9% | +598.3% | +130.1% | +26.1% | +58.0% | +4.1% |
|
PRME
Prime Medicine, Inc.
Peer
|
-75.2% | -72.0% | +207.3% | -30.1% | +7.9% | +11.1% |
PSN
Personalis, Inc.
Primary
5Y
-68.6%
3Y
+152.1%
1Y
+111.0%
6M
-26.3%
1M
-3.3%
1W
+11.8%
BBN
Beta Bionics, Inc.
Peer
5Y
-32.5%
3Y
-32.5%
1Y
-32.5%
6M
+7.5%
1M
-48.7%
1W
-13.7%
GYR
Gyre Therapeutics, Inc.
Peer
5Y
-40.0%
3Y
+134.6%
1Y
+1.4%
6M
-7.2%
1M
-11.3%
1W
+3.8%
ETO
Eton Pharmaceuticals, Inc.
Peer
5Y
+251.9%
3Y
+598.3%
1Y
+130.1%
6M
+26.1%
1M
+58.0%
1W
+4.1%
PRM
Prime Medicine, Inc.
Peer
5Y
-75.2%
3Y
-72.0%
1Y
+207.3%
6M
-30.1%
1M
+7.9%
1W
+11.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-7.12
PEG Ratio
N/A
P/B Ratio
2.64
P/S Ratio
10.11
EV/Revenue
7.3
EV/EBITDA
-6.51
Market Cap
$704.48M
Profitability
Profit margins and return metrics
Profit Margin
-116.69%
Operating Margin
-145.67%
Gross Margin
22.65%
ROE
-35.02%
ROA
-18.21%
Growth
Revenue and earnings growth rates
Revenue Growth
+3.2%
Earnings Growth
N/A
Q/Q Revenue Growth
+3.24%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.17
Low debt
Current Ratio
6.76
Strong
Quick Ratio
6.46
Excellent
Cash/Share
$2.29
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
11.0%
Op. Margin
-145.7%
Net Margin
-137.3%
Total Assets
$0.3B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.28x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-26
$-0.26
+8.8% surprise
2025-11-04
$-0.24
+12.5% surprise
2025-08-05
$-0.23
+5.8% surprise
Healthcare Sector Comparison
Comparing PSNL against 418 companies in the Healthcare sector
(24 bullish, 134 neutral, 260 bearish)
Return on Equity (ROE)
-35.02%
This Stock
vs
-101.05%
Sector Avg
-65.3%
(Below Avg)
Profit Margin
-116.69%
This Stock
vs
-13.75%
Sector Avg
+748.5%
(Superior)
Debt to Equity
0.17
This Stock
vs
3.24
Sector Avg
-94.8%
(Less Debt)
Revenue Growth
3.2%
This Stock
vs
121.5%
Sector Avg
-97.4%
(Slower)
Current Ratio
6.76
This Stock
vs
4.55
Sector Avg
+48.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PSNL
Personalis, Inc.
|
BEARISH | $704.48M | - | -35.0% | -116.7% | $6.73 | |
|
BBNX
Beta Bionics, Inc.
|
BEARISH | $702.63M | - | -47.5% | -87.9% | $15.96 | Compare |
|
GYRE
Gyre Therapeutics, Inc.
|
BEARISH | $711.9M | 369.5 | 8.2% | 4.3% | $7.39 | Compare |
|
ETON
Eton Pharmaceuticals, Inc.
|
BEARISH | $720.17M | - | -18.2% | -5.8% | $26.39 | Compare |
|
PRME
Prime Medicine, Inc.
|
BEARISH | $687.9M | - | -146.8% | -% | $3.81 | Compare |
PSNL
Personalis, Inc.
BEARISH
Mkt Cap
$704M
P/E
-
ROE
-35.0%
Price
$6.73
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | MOORE STEPHEN MICHAEL | Officer | Stock Award | 28,125 | - |
| 2026-03-13 | TACHIBANA AARON | Chief Operating Officer | Stock Award | 34,375 | - |
| 2026-03-13 | HALL CHRISTOPHER M. | Chief Executive Officer | Stock Award | 87,500 | - |
| 2026-03-13 | CHEN RICHARD | President | Stock Award | 46,875 | - |
| 2026-01-22 | TACHIBANA AARON | Chief Operating Officer | Sale | 1,201 | $13,812 |
| 2026-01-22 | TACHIBANA AARON | Chief Operating Officer | Option Exercise | 1,201 | $11,001 |
| 2025-12-22 | TEMPUS AI INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | 320,267 | $2,739,181 |
| 2025-11-25 | TACHIBANA AARON | Chief Operating Officer | Sale | 103,668 | $1,117,541 |
| 2025-11-25 | TACHIBANA AARON | Chief Operating Officer | Option Exercise | 103,668 | $949,599 |
| 2025-11-03 | HALL CHRISTOPHER M. | Chief Executive Officer | Sale | 29,612 | $266,212 |
MOORE STEPHEN MICHAEL
Officer
2026-03-13
28,125 shares
TACHIBANA AARON
Chief Operating Officer
2026-03-13
34,375 shares
HALL CHRISTOPHER M.
Chief Executive Officer
2026-03-13
87,500 shares
CHEN RICHARD
President
2026-03-13
46,875 shares
TACHIBANA AARON
Chief Operating Officer
2026-01-22
1,201 shares
·
$13,812
TACHIBANA AARON
Chief Operating Officer
2026-01-22
1,201 shares
·
$11,001
TEMPUS AI INC
Beneficial Owner of more than 10% of a Class of Security
2025-12-22
320,267 shares
·
$2,739,181
TACHIBANA AARON
Chief Operating Officer
2025-11-25
103,668 shares
·
$1,117,541
TACHIBANA AARON
Chief Operating Officer
2025-11-25
103,668 shares
·
$949,599
HALL CHRISTOPHER M.
Chief Executive Officer
2025-11-03
29,612 shares
·
$266,212
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
8-K
10-K
8-K
10-Q
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
Morgan Stanley
2026-03-05
Equal-Weight
Equal-Weight
Needham
2026-02-27
Buy
Buy
BTIG
2026-02-11
Buy
Buy
Guggenheim
2026-01-26
Buy
Buy
BTIG
2026-01-09
Buy
Buy
Morgan Stanley
2025-12-02
Equal-Weight
Equal-Weight
Morgan Stanley
2025-11-11
Equal-Weight
Equal-Weight
Guggenheim
2025-11-11
Buy
Buy
HC Wainwright & Co.
2025-11-11
Buy
Buy
BTIG
2025-11-11
Buy
Buy
Past News Coverage
Recent headlines mentioning PSNL from our newsroom.
Newest → oldest
No matching news yet.